[{"id":"4bf9de82-bc5d-4f41-96c1-1ff5dcf642d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672524","created_at":"2023-01-05T14:58:33.539Z","updated_at":"2024-07-02T16:35:09.423Z","phase":"Phase 2","brief_title":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer","source_id_and_acronym":"NCT05672524","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • KRAS","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • KRAS exon 2 mutation • RAS wild-type + HER-2 positive • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["HER-2 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • KRAS exon 2 mutation • RAS wild-type + HER-2 positive • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-04-16"},{"id":"75412222-112b-4fb1-9051-534390fb4a85","acronym":"","url":"https://clinicaltrials.gov/study/NCT04554836","created_at":"2021-01-18T21:46:30.517Z","updated_at":"2024-07-02T16:35:10.447Z","phase":"Phase 2","brief_title":"MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab","source_id_and_acronym":"NCT04554836","lead_sponsor":"TheraOp","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation • KRAS exon 2 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 12/29/2020","start_date":" 12/29/2020","primary_txt":" Primary completion: 07/22/2024","primary_completion_date":" 07/22/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-04-10"},{"id":"78a25275-44d9-4dd0-a5b4-65a103b2a67e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03829410","created_at":"2021-01-17T17:16:00.145Z","updated_at":"2024-07-02T16:35:16.847Z","phase":"Phase 1/2","brief_title":"Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation","source_id_and_acronym":"NCT03829410","lead_sponsor":"Cardiff Oncology","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • KRAS exon 2 mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 05/06/2019","start_date":" 05/06/2019","primary_txt":" Primary completion: 01/29/2024","primary_completion_date":" 01/29/2024","study_txt":" Completion: 01/29/2024","study_completion_date":" 01/29/2024","last_update_posted":"2024-03-01"},{"id":"cee8aba7-65f5-4dfb-8178-d79ff5369a64","acronym":"","url":"https://clinicaltrials.gov/study/NCT04999761","created_at":"2021-08-11T15:53:36.773Z","updated_at":"2024-07-02T16:35:19.007Z","phase":"Phase 1","brief_title":"AB122 Platform Study","source_id_and_acronym":"NCT04999761","lead_sponsor":"Taiho Pharmaceutical Co., Ltd.","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Cyramza (ramucirumab) • Lytgobi (futibatinib) • Yutuo (zimberelimab) • Lonsurf (trifluridine/tipiracil) • Jeselhy (pimitespib) • pamufetinib (TAS-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 715","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-02-16"},{"id":"043223c9-1b07-4370-8cca-13212df5199c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05007132","created_at":"2021-08-16T16:54:41.427Z","updated_at":"2024-07-02T16:35:19.202Z","phase":"Phase 2","brief_title":"Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05007132","lead_sponsor":"Dominik Paul Modest","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" RAS mutation • RAS wild-type • KRAS exon 2 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation • RAS wild-type • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Vectibix (panitumumab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 12/01/2029","primary_completion_date":" 12/01/2029","study_txt":" Completion: 12/01/2032","study_completion_date":" 12/01/2032","last_update_posted":"2024-02-15"},{"id":"1171f35b-2865-4fa0-a0a5-c0a8d5d59b76","acronym":"CAVE 2","url":"https://clinicaltrials.gov/study/NCT05291156","created_at":"2022-03-22T12:52:57.473Z","updated_at":"2024-07-02T16:35:21.314Z","phase":"Phase 2","brief_title":"CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy","source_id_and_acronym":"NCT05291156 - CAVE 2","lead_sponsor":"University of Campania \"Luigi Vanvitelli\"","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF wild-type • KRAS exon 2 mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Bavencio (avelumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 173","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-02-01"},{"id":"aa2aa9dd-953c-4710-8346-b00e3dcdc8c6","acronym":"VELO","url":"https://clinicaltrials.gov/study/NCT05468892","created_at":"2022-07-21T11:55:12.137Z","updated_at":"2024-07-02T16:35:21.371Z","phase":"Phase 2","brief_title":"Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial","source_id_and_acronym":"NCT05468892 - VELO","lead_sponsor":"University of Campania \"Luigi Vanvitelli\"","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • KRAS exon 2 mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 10/29/2019","start_date":" 10/29/2019","primary_txt":" Primary completion: 05/31/2022","primary_completion_date":" 05/31/2022","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2024-02-01"},{"id":"8b1ef189-345f-4d0b-8046-65f241c6c7d3","acronym":"CR-SEQUENCE","url":"https://clinicaltrials.gov/study/NCT03635021","created_at":"2021-01-18T17:51:02.237Z","updated_at":"2024-07-02T16:35:24.963Z","phase":"Phase 3","brief_title":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer","source_id_and_acronym":"NCT03635021 - CR-SEQUENCE","lead_sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 419","initiation":"Initiation: 10/15/2018","start_date":" 10/15/2018","primary_txt":" Primary completion: 06/28/2025","primary_completion_date":" 06/28/2025","study_txt":" Completion: 06/28/2025","study_completion_date":" 06/28/2025","last_update_posted":"2023-12-28"},{"id":"31f0020c-0510-41ca-b50a-168b2e6ddd86","acronym":"","url":"https://clinicaltrials.gov/study/NCT03087071","created_at":"2021-01-18T15:12:32.712Z","updated_at":"2024-07-02T16:35:25.486Z","phase":"Phase 2","brief_title":"Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer","source_id_and_acronym":"NCT03087071","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • NRAS • MAP2K1","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • EGFR S492R • KRAS exon 2 wild-type","tags":["KRAS • BRAF • NRAS • MAP2K1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • EGFR S492R • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Vectibix (panitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/29/2017","start_date":" 12/29/2017","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2023-12-21"},{"id":"17a2e003-5254-435c-9222-116e725529ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03808558","created_at":"2021-01-18T18:49:13.553Z","updated_at":"2024-07-02T16:35:25.684Z","phase":"Phase 2","brief_title":"Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas","source_id_and_acronym":"NCT03808558","lead_sponsor":"David E Gerber","biomarkers":" EGFR • KRAS • ALK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • ALK rearrangement • KRAS exon 2 mutation • KRAS exon 12 mutation","tags":["EGFR • KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • ALK rearrangement • KRAS exon 2 mutation • KRAS exon 12 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e denifanstat (TVB-2640)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 09/11/2019","start_date":" 09/11/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-12-20"},{"id":"a7939463-add1-4ee1-b7a9-f0a971710d58","acronym":"FIRE-4","url":"https://clinicaltrials.gov/study/NCT02934529","created_at":"2021-01-18T14:24:36.504Z","updated_at":"2024-07-02T16:35:29.178Z","phase":"Phase 3","brief_title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","source_id_and_acronym":"NCT02934529 - FIRE-4","lead_sponsor":"Ludwig-Maximilians - University of Munich","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Stivarga (regorafenib) • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 673","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-11-15"},{"id":"d396b430-2d8f-45d6-aeae-b6b8e8069381","acronym":"AIO-KRK-0116","url":"https://clinicaltrials.gov/study/NCT04034459","created_at":"2021-01-18T19:47:57.027Z","updated_at":"2024-07-02T16:35:29.371Z","phase":"Phase 2","brief_title":"FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC","source_id_and_acronym":"NCT04034459 - AIO-KRK-0116","lead_sponsor":"Ludwig-Maximilians - University of Munich","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 11/25/2016","start_date":" 11/25/2016","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-11-14"},{"id":"06e0fca2-d97f-4fc4-b976-bea6b4611dff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05694936","created_at":"2023-01-23T14:59:44.826Z","updated_at":"2024-07-02T16:35:30.442Z","phase":"Phase 2","brief_title":"Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05694936","lead_sponsor":"Australasian Gastro-Intestinal Trials Group","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Vectibix (panitumumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 01/23/2023","start_date":" 01/23/2023","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-11-03"},{"id":"dabf61c3-90e1-4c7b-b51c-3e0495df0ca9","acronym":"OSCAR","url":"https://clinicaltrials.gov/study/NCT02885753","created_at":"2021-01-18T14:09:51.809Z","updated_at":"2024-07-02T16:35:39.698Z","phase":"Phase 3","brief_title":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver","source_id_and_acronym":"NCT02885753 - OSCAR","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" KRAS • NRAS • RAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • RAS mutation • KRAS exon 2 mutation","tags":["KRAS • NRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • RAS mutation • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2023-08-17"},{"id":"fe7d37d6-22f3-4c41-9187-22556cd9ff0c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04169347","created_at":"2021-01-18T20:20:29.434Z","updated_at":"2024-07-02T16:35:41.893Z","phase":"Phase 2","brief_title":"FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer","source_id_and_acronym":"NCT04169347","lead_sponsor":"Criterium, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 12/02/2019","start_date":" 12/02/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-07-27"},{"id":"2f454d62-b561-48df-9aa8-c95f396adca9","acronym":"VOLFI","url":"https://clinicaltrials.gov/study/NCT01328171","created_at":"2021-01-18T05:24:48.418Z","updated_at":"2024-07-02T16:35:45.737Z","phase":"Phase 2","brief_title":"FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)","source_id_and_acronym":"NCT01328171 - VOLFI","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" EGFR • KRAS • PIK3CA • NRAS • PTEN • ERCC1 • RAS • MTHFR","pipe":" | ","alterations":" EGFR mutation • PIK3CA mutation • KRAS wild-type • RAS wild-type • EGFR exon 18 mutation • KRAS exon 2 mutation • EGFR mutation + PIK3CA mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["EGFR • KRAS • PIK3CA • NRAS • PTEN • ERCC1 • RAS • MTHFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PIK3CA mutation • KRAS wild-type • RAS wild-type • EGFR exon 18 mutation • KRAS exon 2 mutation • EGFR mutation + PIK3CA mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2023-06-14"},{"id":"73e78a41-52be-4f57-9c1d-0a82cd239ca2","acronym":"PACER","url":"https://clinicaltrials.gov/study/NCT01801904","created_at":"2021-01-18T07:58:37.072Z","updated_at":"2024-07-02T16:35:52.467Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01801904 - PACER","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" KRAS • NRAS • RAS","pipe":" | ","alterations":" RAS mutation • RAS wild-type • KRAS exon 2 mutation","tags":["KRAS • NRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation • RAS wild-type • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Vectibix (panitumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-03-24"},{"id":"18ca4245-a97f-4b96-b71f-8ba49988f234","acronym":"CAVE","url":"https://clinicaltrials.gov/study/NCT04561336","created_at":"2021-01-18T21:47:25.438Z","updated_at":"2024-07-02T16:36:10.951Z","phase":"Phase 2","brief_title":"Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04561336 - CAVE","lead_sponsor":"University of Campania \"Luigi Vanvitelli\"","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • KRAS exon 2 mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Bavencio (avelumab)"],"overall_status":"Completed","enrollment":" Enrollment 77","initiation":"Initiation: 08/10/2018","start_date":" 08/10/2018","primary_txt":" Primary completion: 11/14/2021","primary_completion_date":" 11/14/2021","study_txt":" Completion: 11/14/2021","study_completion_date":" 11/14/2021","last_update_posted":"2022-05-05"},{"id":"0de21748-af3a-488e-89cf-84c99f56357e","acronym":"SAKK 19/16","url":"https://clinicaltrials.gov/study/NCT02964689","created_at":"2021-01-18T14:34:21.117Z","updated_at":"2024-07-02T16:36:27.982Z","phase":"Phase 1","brief_title":"Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.","source_id_and_acronym":"NCT02964689 - SAKK 19/16","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" EGFR • KRAS • ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation • KRAS exon 2 mutation • EGFR mutation + ALK mutation","tags":["EGFR • KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • KRAS exon 2 mutation • EGFR mutation + ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Mektovi (binimetinib) • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/12/2017","start_date":" 04/12/2017","primary_txt":" Primary completion: 07/02/2021","primary_completion_date":" 07/02/2021","study_txt":" Completion: 07/02/2021","study_completion_date":" 07/02/2021","last_update_posted":"2021-07-14"},{"id":"bb4a6aa4-08e9-4d44-bc20-09c982a16bd2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02327169","created_at":"2021-01-18T11:02:33.167Z","updated_at":"2024-07-02T16:36:49.576Z","phase":"Phase 1b","brief_title":"A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies","source_id_and_acronym":"NCT02327169","lead_sponsor":"Millennium Pharmaceuticals, Inc.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF mutation • KRAS exon 2 mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • paclitaxel • irinotecan • sapanisertib (CB-228) • Ojemda (tovorafenib) • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 01/14/2015","start_date":" 01/14/2015","primary_txt":" Primary completion: 07/02/2018","primary_completion_date":" 07/02/2018","study_txt":" Completion: 07/02/2018","study_completion_date":" 07/02/2018","last_update_posted":"2020-02-25"},{"id":"e1bf3faa-d8a3-4dd4-b0b8-8f5accb5cfa1","acronym":"M13DAP","url":"https://clinicaltrials.gov/study/NCT02039336","created_at":"2021-01-18T09:21:38.832Z","updated_at":"2025-02-25T15:33:00.773Z","phase":"Phase 1/2","brief_title":"Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC","source_id_and_acronym":"NCT02039336 - M13DAP","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS exon 2 mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Vizimpro (dacomitinib) • Gomekli (mirdametinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 35","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2018-08-27"},{"id":"47d1845f-aa77-4947-aa19-bc4f53a1a210","acronym":"ColoBEAM","url":"https://clinicaltrials.gov/study/NCT02751177","created_at":"2021-01-18T13:28:47.778Z","updated_at":"2024-07-02T16:37:08.061Z","phase":"","brief_title":"Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02751177 - ColoBEAM","lead_sponsor":"Institut de Cancérologie de Lorraine","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • BRAF V600 • KRAS exon 2 mutation","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • BRAF V600 • KRAS exon 2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 236","initiation":"Initiation: 03/25/2016","start_date":" 03/25/2016","primary_txt":" Primary completion: 05/30/2017","primary_completion_date":" 05/30/2017","study_txt":" Completion: 05/30/2017","study_completion_date":" 05/30/2017","last_update_posted":"2018-08-09"},{"id":"66ba0093-37f8-4c2f-8963-e9c495692bd9","acronym":"CircuLOR-1","url":"https://clinicaltrials.gov/study/NCT02827565","created_at":"2021-01-18T13:51:48.594Z","updated_at":"2024-07-02T16:37:08.102Z","phase":"","brief_title":"Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02827565 - CircuLOR-1","lead_sponsor":"Institut de Cancérologie de Lorraine","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • KRAS exon 2 mutation • BRAF exon 15 mutation","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • KRAS exon 2 mutation • BRAF exon 15 mutation"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/03/2016","start_date":" 02/03/2016","primary_txt":" Primary completion: 01/05/2017","primary_completion_date":" 01/05/2017","study_txt":" Completion: 01/19/2017","study_completion_date":" 01/19/2017","last_update_posted":"2018-08-08"},{"id":"71131880-646c-4064-812c-7652a97cad80","acronym":"RASINTRO","url":"https://clinicaltrials.gov/study/NCT03259009","created_at":"2021-01-18T16:06:02.235Z","updated_at":"2024-07-02T16:37:18.050Z","phase":"","brief_title":"RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO)","source_id_and_acronym":"NCT03259009 - RASINTRO","lead_sponsor":"Association des Gastroentérologues Oncologues","biomarkers":" KRAS • NRAS • RAS","pipe":" | ","alterations":" RAS mutation • KRAS exon 2 mutation","tags":["KRAS • NRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation • KRAS exon 2 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 73","initiation":"Initiation: 10/01/2017","start_date":" 10/01/2017","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 06/01/2020","study_completion_date":" 06/01/2020","last_update_posted":"2017-09-11"}]